{"filing":{"accession_number":"0001193125-26-347854","cik":"0001400118","ticker":"SGMT","company_name":"Sagimet Biosciences Inc.","form":"8-K","filing_date":"2026-08-13","report_date":"2026-08-13","primary_document":"d150919d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1400118/000119312526347854/d150919d8k.htm"},"events":[{"id":27466,"run_id":25038,"accession_number":"0001193125-26-347854","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"The disclosure announces FDA clearance of an IND application and authorization to proceed with a Phase 3 clinical trial for denifanstat in acne treatment. This is a material regulatory milestone for a biopharmaceutical company that advances a key product candidate toward commercialization, affecting investor assessment of the company's pipeline and development progress. The event is operational/strategic in nature rather than fitting a specific named category.","company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","filing_date":"2026-08-13","form":"8-K","submitted_at":null,"items":[{"id":29028,"accession_number":"0001193125-26-347854","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The disclosure announces FDA clearance of an IND application and authorization to proceed with a Phase 3 clinical trial for denifanstat in acne treatment. This is a material regulatory milestone for a biopharmaceutical company that advances a key product candidate toward commercialization, affecting investor assessment of the company's pipeline and development progress. The event is operational/strategic in nature rather than fitting a specific named category.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:06:05.404224+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29028,"accession_number":"0001193125-26-347854","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The disclosure announces FDA clearance of an IND application and authorization to proceed with a Phase 3 clinical trial for denifanstat in acne treatment. This is a material regulatory milestone for a biopharmaceutical company that advances a key product candidate toward commercialization, affecting investor assessment of the company's pipeline and development progress. The event is operational/strategic in nature rather than fitting a specific named category.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:06:05.404224+00:00","company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","filing_date":"2026-08-13"}]}